Patheon, has closed on its previously announced acquisition of IRIX Pharmaceuticals, a Florence, South Carolina.-headquartered company that specializes in making difficult-to-manufacture active pharmaceutical ingredients (API) for drugs from early and late development, through commercial launch.

With the acquisition, Patheon secures additional API development and manufacturing services in the US, including high-potency (SafeBridge Class IV certified) and controlled substances (Schedule 1-4) IRIX has commercial API manufacturing at sites in Greenville and Florence, South Carolina.

IRIX is the second acquisition announced by Patheon this year. In March 2015, Patheon agreed to acquire Agere Pharmaceuticals, a privately held contract development and manufacturing organization, headquartered in Bend, Oregon. Agere specializes in solubilization technologies and related science to improve the bioavailability of drugs.

Source: Patheon